T-cell therapy in combination with checkpoint inhibitors for patients with advanced ovarian-, fallopian tube- and primary peritoneal cancer. T-celle terapi i kombination med checkpoint inhibitorer til patienter med metastatisk ovarie-, tuba- og primær peritoneal cancer.

Trial Profile

T-cell therapy in combination with checkpoint inhibitors for patients with advanced ovarian-, fallopian tube- and primary peritoneal cancer. T-celle terapi i kombination med checkpoint inhibitorer til patienter med metastatisk ovarie-, tuba- og primær peritoneal cancer.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Tumour infiltrating lymphocytes (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top